Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
2.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

3.
4.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
5.

'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.

Rikhof B, van der Graaf WT, Suurmeijer AJ, van Doorn J, Meersma GJ, Groenen PJ, Schuuring EM, Meijer C, de Jong S.

Am J Pathol. 2012 Jul;181(1):303-12. doi: 10.1016/j.ajpath.2012.03.028. Epub 2012 May 29.

PMID:
22658485
6.

Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells.

Tan S, Hougardy BM, Meersma GJ, Schaap B, de Vries EG, van der Zee AG, de Jong S.

Mol Pharmacol. 2012 May;81(5):701-9. doi: 10.1124/mol.111.076539. Epub 2012 Feb 10.

7.

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.

Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S.

Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.

8.

Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.

Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S.

Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10.

9.

Survival-related profile, pathways, and transcription factors in ovarian cancer.

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.

10.

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.

Rikhof B, van der Graaf WT, Meijer C, Le PT, Meersma GJ, de Jong S, Fletcher JA, Suurmeijer AJ.

Br J Cancer. 2008 Nov 18;99(10):1600-6. doi: 10.1038/sj.bjc.6604736. Epub 2008 Oct 21.

11.

Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):543-52. doi: 10.1016/j.ijrobp.2008.06.1902.

PMID:
18793956
12.

A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with Confirmatory Factor Analysis.

Crijns AP, Gerbens F, Plantinga AE, Meersma GJ, de Jong S, Hofstra RM, de Vries EG, van der Zee AG, de Bock GH, te Meerman GJ.

BMC Genomics. 2006 Sep 12;7:232.

13.

Antagonism of HSV-tk transfection and ganciclovir treatment on chemotherapeutic drug sensitivity.

Van Dillen IJ, Mulder NH, Meijer C, Dam WA, Kamstra E, De Vries L, Meersma GJ, Van der Zee AG, De Vries EF, Vaalburg W, Hospers GA.

J Chemother. 2005 Jun;17(3):289-96.

PMID:
16038523
14.

Telomerase in (pre)neoplastic cervical disease.

Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, de Vries EG, Keith WN, van der Zee AG.

Hum Pathol. 2000 Oct;31(10):1304-12.

PMID:
11070123
15.

A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens.

Meersma GJ, Bakker M, Groen HJ, Van der Zee AG, Jensen PB, Giaccone G, De Vries EG, Smit EF.

Anticancer Res. 1999 Mar-Apr;19(2A):1309-15.

PMID:
10368692
16.

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.

Helfrich W, ten Poele R, Meersma GJ, Mulder NH, de Vries EG, de Leij L, Smit EF.

Br J Cancer. 1997;76(1):29-35.

17.

Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer.

Mulder NH, Timmer-Bosscha H, Meersma GJ, Verschueren RC.

Anticancer Res. 1994 Nov-Dec;14(6B):2677-80.

PMID:
7872700
18.

Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.

van der Graaf WT, de Vries EG, Timmer-Bosscha H, Meersma GJ, Mesander G, Vellenga E, Mulder NH.

Cancer Res. 1994 Oct 15;54(20):5368-73.

19.

Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.

Withoff S, Smit EF, Meersma GJ, van den Berg A, Timmer-Bosscha H, Kok K, Postmus PE, Mulder NH, de Vries EG, Buys CH.

Lab Invest. 1994 Jul;71(1):61-6.

PMID:
8041119
20.

Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.

Cancer Res. 1992 Dec 15;52(24):6885-9.

Supplemental Content

Loading ...
Support Center